Cancer name Hepatocellular Carcinoma
Cancer Type LIHC
Immunotherapy type Adoptive Cell Therapy
Treatment Recombinant adenovirus expressing IL-2 (rAd-IL-3)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD4+ T cells
Official Symbol CD4-CD28- T cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental NA
Description To confirm whether HCC mice develop a memory response that protects mice against challenge with the same tumor cells, CD4 and CD8 expression and tumor challenge experiments were conducted after a 120-day survival period. Tumors from rAd-IL -2-treatedmice contained a greater percentage of CD4+and CD8+ T cells compared with PBS<U+2011> and rAd<U+2011>EGFP treated mice, suggesting a greater immune response in these mice.
PMID 29115604
Title Genetically engineered recombinant adenovirus expressing interleukin<U+2011>3 for hepatocellular carcinoma therapy